Sunday, August 31, 2008

Senile plaques, calcium homeostasis and disruption of neuronal networks

Alzheimer's disease is characterized by the deposition of senile plaques and progressive dementia. The molecular mechanisms that couple plaque deposition to neural system failure, however, are unknown. Using transgenic mouse models of AD together with multiphoton imaging, we measured neuronal calcium in individual neurites and spines in vivo using the genetically encoded calcium indicator Yellow Cameleon 3.6. Quantitative imaging revealed elevated [Ca(2+)]i (calcium overload) in approximately 20% of neurites in APP mice with cortical plaques, compared to less than 5% in wild-type mice, PS1 mutant mice, or young APP mice (animals without cortical plaques). Calcium overload depended on the existence and proximity to plaques. The downstream consequences included the loss of spinodendritic calcium compartmentalization (critical for synaptic integration) and a distortion of neuritic morphologies mediated, in part, by the phosphatase calcineurin. Together, these data demonstrate that senile plaques impair neuritic calcium homeostasis in vivo and result in the structural and functional disruption of neuronal networks. ...Neuron. 2008 Jul 31;59(2):214-25

PROBIOTICS

Omega-3 may help survival rates for heart patients: study

A daily supplement of omega-3 polyunsaturated fatty acids may reduce mortality and admission to hospital for cardiovascular reasons in patients with heart failure, says a new study. ...http://www.nutraingredients.com

Get Energy Active!
Posted YVN

Saturday, August 30, 2008

Neonatal iron deficiency may set long-term neurodegenerative disease

Neonatal brain iron deficiency occurs after insufficient maternal dietary iron intake, maternal hypertension, and maternal diabetes mellitus and results in short and long-term neurologic and behavioral deficits. Early iron deficiency affects the genomic profile of the developing hippocampus that persists despite iron repletion. The purpose of the present study was threefold: 1) quantitative PCR confirmation of our previous microarray results, demonstrating upregulation of a network of genes leading to beta-amyloid production and implicated in Alzheimer disease etiology in iron-deficient anemic rat pups at the time of hippocampal differentiation; 2) investigation of the potential contributions of iron deficiency anemia and iron treatment to this differential gene expression in the hippocampus; and 3) investigation of these genes over a developmental time course in a mouse model where iron deficiency is limited to hippocampus, is not accompanied by anemia and is not repletable. Quantitative PCR confirmed altered regulation in 6 of 7 Alzheimer-related genes (Apbb1, C1qa, Clu, App, Cst3, Fn1, Htatip) in iron-deficient rats relative to iron-sufficient controls at P15. Comparison of untreated to treated iron-deficient animals at this age suggested the strong role of iron deficiency, not treatment, in the upregulation of this gene network. The non-anemic hippocampal iron-deficient mouse demonstrated upregulation of all 7 genes in this pathway from P5 to P25. The result suggests a role for neonatal iron deficiency in dysregulation of genes that may set the stage for long-term neurodegenerative disease and that this may occur through a histone modification mechanism. ...Brain Res. 2008 Aug 7.

PROBIOTICS

Green challenge to new pesticide residue rules

Green organisations are instigating legal action over the new maximum legal limits on the level of pesticides... ...http://www.nutraingredients.com

Get Energy Active!
Posted YVN

Friday, August 29, 2008

Verbal ability as a critical marker for degeneration

A new study shows that older people's mental skills start declining years before death, even if they don't have dementia. The study is published in the August 27, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. "These changes are different and separate from the changes in thinking skills that occur as people get older," said study author Valgeir Thorvaldsson, MSc, of Goteberg University in Sweden. "We found accelerated changes in people's mental skills that indicated a terminal decline phase years before death."

The start of the decline is different for various cognitive abilities. Perceptual speed, which measures how quickly people can compare figures, begins declining nearly 15 years before death. Spatial ability starts declining nearly eight years before death. And verbal ability starts declining about six-and-a-half years before death. The study involved 288 people with no dementia who were followed from age 70 to death, with an average age at death of 84. The participants' mental skills were measured up to 12 times over a period of 30 years, and they were evaluated to make sure they had not developed dementia.

A number of factors may explain this terminal decline in mental skills, Thorvaldsson said. "Cardiovascular conditions such as heart disease or dementia that is too early to be detected could be factors," he said. "Increased health problems and frailty in old age often lead to inactivity, and this lack of exercise and mental stimulation could accelerate mental decline." He noted that verbal abilities declined sharply in the terminal phase and did not decline significantly due to age only. "This indicates that people remain stable in their verbal abilities unless they are experiencing disease processes that also increase their mortality risk," he said. "A change in verbal ability might therefore be considered a critical marker for degeneration in health in older people." ...http://www.medicalnewstoday.com

PROBIOTICS

Nano trojan horse delivers antioxidant benefits

Australian researchers have designed a nanoparticle one thousandth the width of a human hair, which they say has demonstrated potential to protect antioxidants from destruction in the gut. ...http://www.nutraingredients.com

Get Energy Active!
Posted YVN

Thursday, August 28, 2008

Novel markers for Alzheimer

Almost 2% of the population of western industrialized countries are affected by Alzheimer's disease (AD). Nevertheless the pathogenetic process leading to this neurodegenerative disease is widely unknown. Scientists hypothesize that AD patients reveal increased levels of peripheral blood mononuclear cells (PBMCs) expressing proinflammatory (COX-2, TNF-alpha, CD40), proapoptotic (PARP-1), adhesion-relevant (CD38) or AD associated (C99, BACE1, Presenilin-1) proteins as well as elevated proinflammatory biochemical plasma parameters. Therefore, PBMCs of AD patients and age-matched control subjects were studied by two color fluorescence-activated cell sorter (FACS) analysis. Furthermore, concentration of plasma oxidized low-density lipoprotein (oxLDL) and TNF-alpha were measured by enzyme-linked immunosorbent assay (ELISA). They found a significantly increased percentage of TNF-alpha, COX-2, PARP-1, CD38, C99 or presenilin-1 positive PBMCs in AD patients compared with healthy subjects. FACS analyses revealed that the percentage of C99 or presenilin-1 positive PBMCs, which also express TNF-alpha, COX-2, PARP-1 or CD38 is also increased in AD patients. Additionally, AD patients had significantly increased plasma oxLDL and TNF-alpha levels. Furthermore, it was found positive correlations between plasma oxLDL or TNF-alpha concentrations and the percentage of TNFalpha (+), COX-2(+) or PARP-1(+), as well as PS-1(+), C99(+) or BACE(+) PBMCs. These findings suggest that immunocytological investigations, based on immunophenotyping of AD relevant proteins combined with measurement of proinflammatory, proapoptotic and adhesion-relevant proteins in PBMCs may provide more insight into the pathophysiology of AD. Curr Alzheimer Res. 2008 Aug;5(4):358-66.

PROBIOTICS

Black raspberries show potential against cancer

Concentrated freeze-dried extracts from black raspberries may help prevent certain cancers by acting on multiple gene targets, suggests a new study with rats. ...http://www.nutraingredients.com

Get Energy Active!
Posted YVN

Wednesday, August 27, 2008

Signaling in hippocampal neurons

Scientists report that interruption of NGF or BDNF signaling in hippocampal neurons rapidly activates the amyloidogenic pathway and causes neuronal apoptotic death. These events are associated with an early intracellular accumulation of PS1 N-terminal catalytic subunits and of APP C-terminal fragments and a progressive accumulation of intra- and extracellular Aβ aggregates partly released into the culture medium. The released pool of Aβ induces an increase of APP and PS1 holoprotein levels, creating a feed-forward toxic loop that might also cause the death of healthy neurons. These events are mimicked by exogenously added Aβ and are prevented by exposure to β- and γ-secretase inhibitors and by antibodies directed against Aβ peptides. The same cultured neurons deprived of serum die, but APP and PS1 overexpression does not occur, Aβ production is undetectable, and cell death is not inhibited by anti-Aβ antibodies, suggesting that hippocampal amyloidogenesis is not a simple consequence of an apoptotic trigger but is due to interruption of neurotrophic signaling. http://www.pnas.org/content/early/2008/08/25/0806133105

PROBIOTICS

Olive leaf extract shows heart benefits: Frutarom study

Extracts from olive leaves may help reduce cholesterol and blood pressure levels, according to a small human study from Israel-based supplier Frutarom. ...http://www.nutraingredients.com

Get Energy Active!
Posted YVN

Tuesday, August 26, 2008

Gamma-secretase modulators: with respect to Alzheimer's

A new class of drugs called gamma-secretase modulators work to reduce the buildup of toxic proteins in the brains of people with Alzheimer’s disease, giving doctors hope that these medications may offer effective new treatments for the devastating brain ailment. Results of advanced-stage testing of one of these drugs, called Flurizan, failed to show any benefit, though this unfortunate failure does not signal that other drugs, based on the same principle – called gamma-secretase modulation -- will fail.

Researchers at the Mayo Clinic report that gamma-secretase modulators work to reduce the production of long pieces of a protein called beta-amyloid that builds up in the brains of those with the disease. These drugs also appear to promote the production of shorter forms of beta-amyloid that may inhibit the longer forms from sticking together and forming brain-damaging clumps. Doctors have long known that beta-amyloid builds up in the brains of people with Alzheimer’s disease. But scientists still don’t know exactly why or how this occurs, and how it may lead to the onset of memory loss and dementia.

Beta-amyloid by itself it not necessarily bad. It is formed from a larger protein called amyloid precursor protein, or APP, that can be snipped into shorter segments by proteins called enzymes. One of these enzymes is called gamma secretase. Gamma secretase acts on a fragment of APP, shearing it like a pair of molecular scissors into smaller fragments of beta-amyloid of varying length.

One resulting form of beta-amyloid, consisting of 42 protein building blocks called amino acids, appears to be particularly toxic to the brain. This 42-amino acid form of beta-amyloid is the main form that builds up in the brains of those with Alzheimer’s disease to form plaques. A hallmark of Alzheimer's is the formation of these plaques, which are believed to damage neurons in complex ways that are not yet fully understood. But beta-amyloid also exists in shorter forms, like the 38- and 40-amino acid segments that appear to be less harmful. These shorter segments may even be beneficial, helping to prevent the longer, and toxic, 42-amino acid form from sticking together to form plaques.

The new drugs, the gamma secretase modulators, are believed to act on APP, rather than the gamma secretase enzyme directly. As a result, when gamma secretase shears the larger APP protein, it tends to form shorter snippets of nontoxic beta-amyloid. At the same time, less of the toxic form of beta-amyloid is produced.

"So, as these compounds lower the amount of the bad, longer sticky beta-amyloid peptides in the brain, they increase the quantity of shorter beta-amyloid peptides that may protect against development of Alzheimer's disease," said the study’s senior author, Todd Golde, M.D., Ph.D., Chair of the Department of Neuroscience at the Mayo Clinic in Jacksonville. "In a very general sense the action of these gamma secretase modulators on beta-amyloid might be analogous to some cholesterol-lowering drugs that can lower LDL, the bad cholesterol that sticks to your arteries, and can raise HDL, the good cholesterol," Dr. Golde said.

There is also some evidence that the gamma secretase modulators actually stick to the toxic beta-amyloid already in the brain, keeping it from clumping together. "Surprisingly, this means that these compounds may do three things that may be beneficial with respect to Alzheimer's disease: they inhibit production of long beta-amyloid, may block aggregation of beta-amyloid, and increase production of shorter beta-amyloid peptides that may in turn inhibit beta-amyloid aggregation," said the study's lead investigator, Thomas Kukar, Ph.D. Because these experimental drugs lower levels of toxic beta-amyloid, they are sometimes also referred to as selective amyloid lowering agents, or SALAs. ...http://www.alzinfo.org

PROBIOTICS

Mushroom extract demonstrates immunity benefits

Japanese researchers in conjunction with the Yale School of Medicine have found the mushroom extract, AHCC, can strengthen the immune system and fight the onset of cancer among over-50s. ...http://www.nutraingredients.com

Get Energy Active!
Posted YVN

Monday, August 25, 2008

New therapeutic approaches to protect neurons from inflammation

New research at LSU Health Sciences Center New Orleans, provides evidence that one of the only naturally occurring fatty acids in the brain that has the ability to interact with the receptors originally identified as the targets of THC (the psychoactive component of marijuana) can help to protect brain cells from neurodegenerative diseases like Alzheimer's and Parkinson's. Published in the Journal of Biological Chemistry, the research focuses on the cellular and molecular mechanisms of inflammation, specifically the role these relatively recently discovered endogenous cannabinoids can play in the control of COX-2 and other cyclooxygenases. COX-2 is a key player in neuroinflammation and has been implicated in the development of neurodegenerative diseases and worsening of damage from such insults as traumatic brain injury and stroke.

Scientists show that endocannabinoid 2-arachidonoylglycerol (2-AG) functions as an endogenous COX-2 inhibitor, turning off the production of COX-2 which normally goes into overdrive in response to pro-inflammatory and certain types of toxic stimuli, resulting in the injury or death of brain cells. The researchers also revealed the specific signaling pathways that regulate the 2-AG suppression of COX-2. Findings provide a basis for opening up new therapeutic approaches to protect neurons from inflammation and toxicity-induced neurodegeneration. Selective COX-2 inhibitors were thought to be a promising medicine in treating neurodegenerative diseases, stroke, cancers and inflammation-related diseases like arthritis; however, the occurrence of a series of cardiovascular complications in patients receiving COX-2 inhibitors has led to their recent withdrawal from the market and limits on their usages. This research has shown that the use of endogenous cannabinoid 2-AG may avoid such side effects. Therefore, elevation of endogenous 2-AG levels by facilitating its production, inhibiting its decomposition, or directly supplying 2-AG may result in treatment advances to prevent the devastation of disorders like stroke, Alzheimer's and traumatic brain injury. ...http://www.medicalnewstoday.com

PROBIOTICS

Omega-3 reality check

The market predictions for omega-3 products are endlessly buoyant but a closer look at the state of play reveals very few omega-3 functional foods and beverages have moved beyond niche sales levels. ...http://www.nutraingredients.com

Get Energy Active!
Posted YVN